| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4593098af5062ecc1b104b5bde87ae5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 |
| filingDate |
2019-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65dfc325ae9857808ee2d0746df90345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49ea9b0689d9da9df81a0a6e87b5700b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_101df4fa10da839e61b53dcaabe3a744
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96d9a322277ad7d9f70d90cf7c1a0ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c9d2669b6ebda45f06ed1e2c18bec7 |
| publicationDate |
2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020008442-A3 |
| titleOfInvention |
Biopharmaceutical agents for use in reducing lipid content in cells |
| abstract |
This disclosure relates to a biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/ high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. The disclosure also relates to a method of decreasing lipid concentration in a target cell of a human or animal subject. |
| priorityDate |
2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |